Facultad de Ciencias de la Salud

URI permanente para esta comunidad

http://repositorioabierto.uantof.cl/handle/uantof/2

Examinar

Examinando Facultad de Ciencias de la Salud por Autor "Alejandro Piña Iturbe"

Mostrando 1 - 1 de 1
  • No hay miniatura disponible
    Ítem
    Inactivated Vaccine-Induced SARS-CoV-2 Variant-SpecificImmunity in Children
    (2022) Jorge A. Soto; Felipe Melo González; Cristián Gutierrez Vera; Bárbara M. Schultz; Roslye V. Berríos Rojas; Daniela Rivera Pérez; Alejandro Piña Iturbe; Guillermo Hoppe Elsholz; Luisa F. Duarte; Yaneisi Vázquez; Daniela Moreno Tapia; Mariana Ríos; Pablo A. Palacios; Richard Garcia Betancourt; Álvaro Santibañez; Gaspar A. Pacheco; Constanza Mendez; Catalina A. Andrade; Pedro H. Silva; Benjamín Diethelm Varela; Patricia Astudillo; Mario Calvo; Antonio Cárdenas; Marcela González; Macarena Goldsack; Valentina Gutiérrez; Marcela Potin; Andrea Schilling; Lorena I. Tapia; Loreto Twele; Rodolfo Villena; Alba Grifoni; Alessandro Sette; Daniela Weiskopf; Rodrigo A. Fasce; Jorge Fernández; Judith Mora; Eugenio Ramírez; Aracelly Gaete Argel; Mónica L. Acevedo; Fernando Valiente Echeverría; Ricardo Soto Rifo; Angello Retamal Díaz; Nathalia Muñoz Jofré; PedCoronaVac03CL Study Group; Xing Meng; Qianqian Xin; Eduardo Alarcón Bustamante; José V. González Aramundiz; Nicole Le Corre; María Javiera Álvarez Figueroa; Pablo A. González; Katia Abarca; Cecilia Perret; Leandro J. Carreño; Susan M. Bueno; Alexis M. Kalergis
    Multiple vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been evaluated in clinical trials. However, trials addressing the immune response in the pediatric population are scarce. The inactivated vaccine CoronaVac has been shown to be safe and immunogenic in a phase 1/2 clinical trial in a pediatric cohort in China. Here, we report interim safety and immunogenicity results of a phase 3 clinical trial for CoronaVac in healthy children and adolescents in Chile. Participants 3 to 17 years old received two doses of CoronaVac in a 4-week interval until 31 December 2021. Local and systemic adverse reactions were registered for volunteers who received one or two doses of CoronaVac. Whole-blood samples were collected from a subgroup of 148 participants for humoral and cellular immunity analyses. The main adverse reaction reported after the first and second doses was pain at the injection site. Four weeks after the second dose, an increase in neutralizing antibody titer was observed in subjects relative to their baseline visit. Similar results were found for activation of specific CD41 T cells. Neutralizing antibodies were identified against the Delta and Omicron variants. However, these titers were lower than those for the D614G strain. Importantly, comparable CD41 T cell responses were detected against these variants of concern. Therefore, CoronaVac is safe and immunogenic in subjects 3 to 17 years old, inducing neutralizing antibody secretion and activating CD41 T cells against SARS-CoV-2 and its variants. (This study has been registered at ClinicalTrials .gov under no. NCT04992260.)